Macrocyclic Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonists.
暂无分享,去创建一个
F. Vajdos | M. Schnute | M. Vazquez | J. Knafels | R. Unwalla | Alexandria P. Taylor | Andrew C Flick | P. Nuhant | Katherine L Lee | G. Berstein | Yajuan Zhao | K. Crouse | B. Kauppi | Amy L Brault | Katherine L. Lee | J. Trujillo | Amanda Samuel | Vincent Lombardo | Philippe Nuhant
[1] C. Gege. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently? , 2021, Expert opinion on drug discovery.
[2] Michael Albers,et al. Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534 , 2021, Scientific Reports.
[3] Michael G. Yang,et al. Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis. , 2021, ACS medicinal chemistry letters.
[4] K. Beaumont,et al. A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis , 2020, Clinical and experimental dermatology.
[5] S. Shuto,et al. Discovery of [1,2,4]Triazolo[1,5-a]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse Agonists. , 2020, ACS medicinal chemistry letters.
[6] R. Pehrson,et al. Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid‐related orphan receptor γ agonist AZD0284 , 2020, British journal of clinical pharmacology.
[7] N. Tsuchimori,et al. Pharmacological evaluation of TAK-828F, a novel orally available RORγt inverse agonist, on murine chronic experimental autoimmune encephalomyelitis model , 2019, Journal of Neuroimmunology.
[8] T. Kanai,et al. Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease , 2019, Inflammation Research.
[9] David C. Wood,et al. Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist. , 2018, Journal of medicinal chemistry.
[10] W. Wigger‐Alberti,et al. A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test , 2018, The British journal of dermatology.
[11] Mark J. Mitton-Fry,et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. , 2018, Journal of medicinal chemistry.
[12] M. Veldhoen. Interleukin 17 is a chief orchestrator of immunity , 2017, Nature Immunology.
[13] 2nd Inflammatory Skin Disease Summit, November 16-19, 2016, New York. , 2016, Experimental dermatology.
[14] C. Ottmann,et al. Identification of an allosteric binding site for RORγt inhibition , 2015, Nature Communications.
[15] R. Grubbs,et al. Ruthenium-based heterocyclic carbene-coordinated olefin metathesis catalysts. , 2010, Chemical reviews.
[16] D. Littman,et al. The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.
[17] K. Nicolaou,et al. Metathesis reactions in total synthesis. , 2005, Angewandte Chemie.
[18] Jan H. van Maarseveen,et al. Synthesis of 2-substituted piperazines via direct α-lithiation , 2005 .
[19] B. Yang,et al. Mild and Selective Debenzylation of Tertiary Amines Using α-Chloroethyl Chloroformate , 1993 .
[20] T Yano,et al. Skin permeability of various non-steroidal anti-inflammatory drugs in man. , 1986, Life sciences.